Periodic Reporting for period 1 - de-ALARMIN (Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis)

Our previous work within the ERC Stg grant “deFiber” demonstrated that a drug called tasquinimod can ameliorate a chronic blood cancer (myeloproliferative neoplasms; MPN) which is associated with life-limiting fibrosis of the bone marrow. The data presented in our...